此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Ephedrine Versus Norepinephrine and Fetal Acid-Base Status During Cesarean Delivery Under Spinal Anesthesia (NEO-FET)

2026年10月4日 更新者:mehmet özkılıç

Comparative Effects of Ephedrine and Norepinephrine on Fetal Acid-Base Status During Cesarean Delivery Under Spinal Anesthesia: A Randomized Double-Blind Study

This study compares ephedrine and norepinephrine for the treatment of low blood pressure (hypotension) that may occur during cesarean delivery under spinal anesthesia. Maternal hypotension can reduce uteroplacental blood flow and may affect fetal well-being. Both medications are commonly used to restore blood pressure. The primary aim of this study is to compare their effects on neonatal acid-base status, assessed by umbilical arterial pH measured immediately after birth. Secondary outcomes include other umbilical arterial blood gas parameters, maternal blood pressure and heart rate, vasopressor requirements, maternal adverse events, and neonatal Apgar scores.

研究概览

详细说明

This is a prospective, randomized, double-blind, controlled clinical trial designed to compare the effects of ephedrine and norepinephrine on fetal acid-base status during elective cesarean delivery under spinal anesthesia. Maternal hypotension is a common complication of spinal anesthesia and may reduce uteroplacental perfusion. Ephedrine and norepinephrine are both used to restore maternal blood pressure, but their comparative effects on fetal acid-base balance and maternal hemodynamics remain incompletely defined.

The primary aim of the study is to compare umbilical arterial pH between patients treated with ephedrine and those treated with norepinephrine for postspinal hypotension. Secondary outcomes include other umbilical arterial blood gas parameters, including pCO₂, bicarbonate, base excess, and lactate; the incidence of neonatal acidosis defined as umbilical arterial pH <7.20; Apgar scores at 1 and 5 minutes; maternal systolic blood pressure and heart rate; vasopressor requirements; and maternal adverse events.

A total of 155 parturients were randomized in a 1:1 ratio before spinal anesthesia. Because the study drugs were administered only when postspinal hypotension occurred, the analysis population consisted of randomized participants who developed hypotension and received the allocated vasopressor. This resulted in 102 participants in the final analysis population, including 50 in the ephedrine group and 52 in the norepinephrine group.

All randomized participants underwent a standardized spinal anesthesia protocol. Postspinal hypotension was treated with repeated intravenous boluses of either ephedrine 5 mg or norepinephrine 5 µg according to the allocated treatment arm. The study was designed to compare fetal acid-base effects and maternal hemodynamic responses associated with these two vasopressor strategies.

研究类型

介入性

注册 (实际的)

155

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Diyarbakır、土耳其(türkiye)、21070
        • SBÜ Gazi Yaşargil Eğitim ve Araştırma Hastanesi

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

不

有资格学习的性别

女性

描述

nclusion Criteria:

  • Women aged 18-45 years
  • Singleton term pregnancy (≥37 weeks of gestation)
  • American Society of Anesthesiologists (ASA) physical status I-II
  • Scheduled for elective cesarean delivery under spinal anesthesia

Exclusion Criteria:

  • Hypertensive disorders of pregnancy
  • Known systemic disease
  • Multiple gestation
  • Emergency cesarean delivery
  • Contraindication to spinal anesthesia
  • Known allergy to the study medications
  • Pre-diagnosed fetal growth restriction identified using standardized growth curves and pathological Doppler findings
  • Suspected fetal distress
  • Oligohydramnios
  • Known congenital fetal anomalies

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
有源比较器:Ephedrine Group

Participants allocated to this group received intravenous ephedrine 5 mg boluses for the treatment of postspinal hypotension. Additional 5 mg boluses were administered at 1-minute intervals as needed until the predefined blood pressure target was achieved.

Intravenous ephedrine 5 mg bolus administered for the treatment of postspinal hypotension during elective cesarean delivery. Additional 5 mg boluses were administered at 1-minute intervals as needed until the predefined blood pressure target was achieved.

其他名称:
  • 盐酸麻黄碱
实验性的:Norepinephrine Group

Participants allocated to this group received intravenous norepinephrine 5 µg boluses for the treatment of postspinal hypotension. Additional 5 µg boluses were administered at 1-minute intervals as needed until the predefined blood pressure target was achieved.

Intravenous norepinephrine 5 µg bolus administered for the treatment of postspinal hypotension during elective cesarean delivery. Additional 5 µg boluses were administered at 1-minute intervals as needed until the predefined blood pressure target was achieved.

其他名称:
  • Steradin®

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Umbilical arterial pH
大体时间:Immediately after delivery

Umbilical arterial pH measured immediately after delivery from an arterial blood sample obtained from a double-clamped segment of the umbilical cord and analyzed within 5 minutes using a blood gas analyzer.

Immediately after delivery

次要结果测量

结果测量
措施说明
大体时间
Maternal hypotension
大体时间:From spinal anesthesia until delivery

Postspinal hypotension was defined as a decrease in systolic blood pressure to less than 80% of the baseline value. The number and duration of hypotensive episodes were recorded.

From spinal anesthesia until delivery
Incidence of neonatal acidosis (UA pH <7.20)
大体时间:Immediately after delivery

Incidence of neonatal acidosis, defined as an umbilical arterial pH <7.20, determined from an umbilical arterial blood sample obtained immediately after delivery and analyzed using a point-of-care blood gas analyzer.

Immediately after delivery
Maternal heart rate response
大体时间:From spinal anesthesia until delivery / during surger

Maternal heart rate was recorded after spinal anesthesia and during periods requiring vasopressor administration. Temporal heart rate changes and the occurrence of tachycardia were recorded.

From spinal anesthesia until delivery / during surger

其他结果措施

结果测量
措施说明
大体时间
Apgar score at 1 minute
大体时间:At 1 minute after delivery

Apgar Score (Appearance, Pulse, Grimace, Activity, Respiration) will be assessed by the attending neonatologist. The score ranges from 0 to 10, where higher scores indicate better neonatal condition. The outcome is the distribution of Apgar scores at 1 minute after birth.

At 1 minute after delivery
Apgar score at 5 minutes
大体时间:At 5 minutes after delivery

Apgar Score (Appearance, Pulse, Grimace, Activity, Respiration) will be assessed by the attending neonatologist. The score ranges from 0 to 10, where higher scores indicate better neonatal condition. The outcome is the distribution of Apgar scores at 5 minutes after birth.

At 5 minutes after delivery
Requirement for additional vasopressor doses
大体时间:During surgery

The number of vasopressor boluses and the total amount of ephedrine (mg) or norepinephrine (µg) administered for treatment of postspinal hypotension were recorded.

During surgery
Neonatal heart rate after delivery
大体时间:Immediately after delivery

Neonatal heart rate measured after delivery and compared between the ephedrine and norepinephrine groups.

Immediately after delivery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mehmet ÖZKILIÇ, Anesthesiology and Intensive Care Specialist, MD、Gazi Yaşargil Training and Research Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月1日

初级完成 (实际的)

2025年12月1日

研究完成 (实际的)

2025年12月1日

研究注册日期

首次提交

2025年4月1日

首先提交符合 QC 标准的

2025年4月8日

首次发布 (实际的)

2025年4月10日

研究记录更新

最后更新发布 (实际的)

2026年10月8日

上次提交的符合 QC 标准的更新

2026年10月4日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

IPD will not be shared because data sharing was not included in the approved study protocol.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅